Cross‐sectional analysis reveals autoantibody signatures associated with COVID‐19 severity

The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection is associated with increased levels of autoantibodies targeting immunological proteins such as cytokines and chemokines. Reports further indicate that COVID‐19 patients may develop a broad spectrum of autoimmune diseases due to reasons not fully understood. Even so, the landscape of autoantibodies induced by SARS‐CoV‐2 infection remains uncharted territory. To gain more insight, we carried out a comprehensive assessment of autoantibodies known to be linked to diverse autoimmune diseases observed in COVID‐19 patients in a cohort of 231 individuals, of which 161 were COVID‐19 patients (72 with mild, 61 moderate, and 28 with severe disease) and 70 were healthy controls. Dysregulated IgG and IgA autoantibody signatures, characterized mainly by elevated concentrations, occurred predominantly in patients with moderate or severe COVID‐19 infection. Autoantibody levels often accompanied anti‐SARS‐CoV‐2 antibody concentrations while stratifying COVID‐19 severity as indicated by random forest and principal component analyses. Furthermore, while young versus elderly COVID‐19 patients showed only slight differences in autoantibody levels, elderly patients with severe disease presented higher IgG autoantibody concentrations than young individuals with severe COVID‐19. This work maps the intersection of COVID‐19 and autoimmunity by demonstrating the dysregulation of multiple autoantibodies triggered during SARS‐CoV‐2 infection. Thus, this cross‐sectional study suggests that SARS‐CoV‐2 infection induces autoantibody signatures associated with COVID‐19 severity and several autoantibodies that can be used as biomarkers of COVID‐19 severity, indicating autoantibodies as potential therapeutical targets for these patients.

[1]  W. Verschuren,et al.  Using random forest to identify longitudinal predictors of health in a 30-year cohort study , 2022, Scientific Reports.

[2]  W. Verschuren,et al.  Using random forest to identify longitudinal predictors of health in a 30-year cohort study , 2022, Scientific Reports.

[3]  J. LaBaer,et al.  Serum autoantibodyome reveals that healthy individuals share common autoantibodies. , 2022, Cell reports.

[4]  J. Silverberg,et al.  Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity , 2022, Nature Communications.

[5]  H. Jumaa,et al.  Autoreactive antibodies control blood glucose by regulating insulin homeostasis , 2022, Proceedings of the National Academy of Sciences.

[6]  C. Grove,et al.  Cerebral arterial and venous thrombosis due to COVID-19 vaccine-induced immune thrombotic thrombocytopenia , 2022, BMJ Case Reports.

[7]  G. Middleton,et al.  A highly predictive autoantibody-based biomarker panel for prognosis in early-stage NSCLC with potential therapeutic implications , 2021, British journal of cancer.

[8]  J. Casanova,et al.  The intersection of COVID-19 and autoimmunity. , 2021, The Journal of clinical investigation.

[9]  J. Wisnivesky,et al.  Assessment of Cognitive Function in Patients After COVID-19 Infection , 2021, JAMA network open.

[10]  hong wang,et al.  Correlation Analysis of Anti-Cardiolipin Antibody/D Dimer/C-Reactive Protein and Coronary Artery Lesions/Multiple-Organ Damage in Children With Kawasaki Disease , 2021, Frontiers in Pediatrics.

[11]  Shaun M. Kandathil,et al.  A guide to machine learning for biologists , 2021, Nature Reviews Molecular Cell Biology.

[12]  H. Gao,et al.  SARS-CoV-2 crosses the blood–brain barrier accompanied with basement membrane disruption without tight junctions alteration , 2021, Signal Transduction and Targeted Therapy.

[13]  E. Verdin,et al.  SARS-CoV-2, COVID-19 and the aging immune system , 2021, Nature Aging.

[14]  H. Ochs,et al.  The relationship between autoantibodies targeting GPCRs and the renin-angiotensin system associates with COVID-19 severity , 2021, medRxiv.

[15]  A. Jahangiri,et al.  SARS-CoV-2 Proteome Harbors Peptides Which Are Able to Trigger Autoimmunity Responses: Implications for Infection, Vaccination, and Population Coverage , 2021, Frontiers in Immunology.

[16]  J. Silverberg,et al.  Association of Varying Clinical Manifestations and Positive Anti–SARS-CoV-2 IgG Antibodies: A Cross-Sectional Observational Study , 2021, The Journal of Allergy and Clinical Immunology: In Practice.

[17]  C. Reutelingsperger,et al.  Development of IgG, IgM, and IgA autoantibodies against angiotensin converting enzyme 2 in patients with COVID-19. , 2021, The journal of applied laboratory medicine.

[18]  R. Harvey,et al.  Application of the random forest algorithm to Streptococcus pyogenes response regulator allele variation: from machine learning to evolutionary models , 2021, Scientific Reports.

[19]  Eric Pellegrino,et al.  Machine learning random forest for predicting oncosomatic variant NGS analysis , 2021, Scientific Reports.

[20]  M. Boldrini,et al.  How COVID-19 Affects the Brain. , 2021, JAMA psychiatry.

[21]  J. Silverberg,et al.  SARS-CoV-2 Seroprevalence and Symptom Onset in Culturally Linked Orthodox Jewish Communities Across Multiple Regions in the United States , 2021, JAMA network open.

[22]  S. Merler,et al.  Association of Age With Likelihood of Developing Symptoms and Critical Disease Among Close Contacts Exposed to Patients With Confirmed SARS-CoV-2 Infection in Italy , 2021, JAMA network open.

[23]  Y. Shoenfeld,et al.  The SARS-CoV-2 as an instrumental trigger of autoimmunity , 2021, Autoimmunity Reviews.

[24]  B. Maček,et al.  IgA autoantibodies target pulmonary surfactant in patients with severe COVID-19 , 2021, medRxiv.

[25]  S. Jauhiainen,et al.  Comparison of feature importance measures as explanations for classification models , 2021, SN Applied Sciences.

[26]  E. Wherry,et al.  New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19 , 2021, medRxiv.

[27]  Roxanne Khamsi.  Rogue antibodies could be driving severe COVID-19 , 2021, Nature.

[28]  B. Howlin,et al.  Random forest classification for predicting lifespan-extending chemical compounds , 2020, Scientific Reports.

[29]  Givanna H. Putri,et al.  Integrated immune dynamics define correlates of COVID-19 severity and antibody responses , 2020, Cell Reports Medicine.

[30]  R. McIntyre,et al.  Impact of SARS-CoV-2 Infection on Cognitive Function: A Systematic Review , 2021, Frontiers in Psychiatry.

[31]  R. Würzner,et al.  The Complex Role of Regulatory T Cells in Immunity and Aging , 2021, Frontiers in Immunology.

[32]  A. Vojdani,et al.  Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases , 2021, Frontiers in Immunology.

[33]  Q. Lu,et al.  COVID-19 and autoimmune diseases , 2020, Current opinion in rheumatology.

[34]  Elizabeth B White,et al.  Diverse Functional Autoantibodies in Patients with COVID-19 , 2020, Nature.

[35]  W. Banks,et al.  The S1 protein of SARS-CoV-2 crosses the blood–brain barrier in mice , 2020, Nature Neuroscience.

[36]  M. Wener,et al.  Prevalence of autoantibody responses in acute coronavirus disease 2019 (COVID-19) , 2020, Journal of Translational Autoimmunity.

[37]  J. Knight,et al.  Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19 , 2020, Science Translational Medicine.

[38]  Y. Shoenfeld,et al.  SARS-CoV-2, the autoimmune virus , 2020, Autoimmunity Reviews.

[39]  I. Sanz,et al.  Relaxed peripheral tolerance drives broad de novo autoreactivity in severe COVID-19 , 2020 .

[40]  Samuel M. Brown,et al.  Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study , 2020, The Lancet Rheumatology.

[41]  Steven M. Holland,et al.  Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.

[42]  N. Loman,et al.  Post-acute COVID-19 associated with evidence of bystander T-cell activation and a recurring antibiotic-resistant bacterial pneumonia , 2020, medRxiv.

[43]  M. Ehrenfeld,et al.  Covid-19 and autoimmunity , 2020, Autoimmunity Reviews.

[44]  A. Vojdani,et al.  Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases , 2020, Clinical Immunology.

[45]  Tadahiro Goto,et al.  Machine Learning–Based Prediction of Clinical Outcomes for Children During Emergency Department Triage , 2019, JAMA network open.

[46]  B. Engelhardt,et al.  GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis , 2018, Nature Communications.

[47]  L. Ferrucci,et al.  Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty , 2018, Nature Reviews Cardiology.

[48]  G. Riemekasten,et al.  Functional autoantibodies targeting G protein-coupled receptors in rheumatic diseases , 2017, Nature Reviews Rheumatology.

[49]  A. Beyer,et al.  A random forest approach to capture genetic effects in the presence of population structure , 2015, Nature Communications.

[50]  B. Bogerts,et al.  Prevalence of N-methyl-D-aspartate receptor autoantibodies in the peripheral blood: healthy control samples revisited. , 2014, JAMA psychiatry.

[51]  Ruth R. Montgomery,et al.  Age-dependent dysregulation of innate immunity , 2013, Nature Reviews Immunology.

[52]  Robert G. Nagele,et al.  Natural IgG Autoantibodies Are Abundant and Ubiquitous in Human Sera, and Their Number Is Influenced By Age, Gender, and Disease , 2013, PloS one.

[53]  P. Khatri,et al.  Profiling of autoantibodies in IgA nephropathy, an integrative antibiomics approach. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[54]  Y. Shoenfeld,et al.  Clinical and Molecular Evidence for Association of SLE with parvovirus B19 , 2010, Lupus.

[55]  G. Silverman,et al.  Natural autoantibodies to apoptotic cell membranes regulate fundamental innate immune functions and suppress inflammation. , 2009, Discovery medicine.

[56]  H. Lutz,et al.  Naturally occurring auto-antibodies in homeostasis and disease. , 2009, Trends in immunology.

[57]  Heng Tao Shen,et al.  Principal Component Analysis , 2009, Encyclopedia of Biometrics.

[58]  Y. Shoenfeld,et al.  Viral infection can induce the production of autoantibodies , 2007, Current opinion in rheumatology.

[59]  N. Keicho,et al.  Anti‐cytokine autoantibodies are ubiquitous in healthy individuals , 2007, FEBS letters.

[60]  Yao-Hsu Yang,et al.  Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)‐associated coronavirus infection , 2005, Journal of medical virology.